This is an international, multicenter, open label extension trial to collect further safety, tolerability, efficacy, durability, and clinical outcomes of apraglutide once weekly adminstration, for up to an additional 104 weeks. Eligible subjects would be those who have successfully completed TA799-007 or TA799-013 trials.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.